Ascendis Pharma A (ASND) Long-Term Deferred Tax (2023 - 2026)

Ascendis Pharma A (ASND) has 4 years of Long-Term Deferred Tax data on file, last reported at $808.3 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $808.3 million; the trailing twelve-month figure through Mar 2026 stood at $808.3 million (changed N/A YoY), and the FY2025 full-year result was -$11.2 million, down 42.59% from the prior year.
• Long-Term Deferred Tax grew to $808.3 million in Q1 2026, from -$11.2 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $808.3 million in Q1 2026 to a low of -$11.2 million in Q4 2025.
• A 4-year average of $195.8 million and a median of -$7.0 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax fell 23.64% in 2024 and slumped 44.43% in 2025, its largest moves.
• Tracing ASND's Long-Term Deferred Tax over 4 years: stood at -$6.3 million in 2023, then decreased by 23.64% to -$7.8 million in 2024, then slumped by 44.43% to -$11.2 million in 2025, then surged by 7315.84% to $808.3 million in 2026.
• Business Quant data shows ASND's Long-Term Deferred Tax at $808.3 million in Q1 2026, -$11.2 million in Q4 2025, and -$7.8 million in Q4 2024.